23:54 , Aug 4, 2017 |  BioCentury  |  Finance

Fungal flexibility

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...
16:47 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures on Aug. 2. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas...
20:40 , Aug 2, 2017 |  BC Extra  |  Financial News

Amplyx raises $67M in series C

Anti-infectives company Amplyx Pharmaceuticals Inc. (San Diego, Calif.) raised $67 million in an oversubscribed series C round led by Sofinnova Ventures. Also participating were new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, and existing...
02:48 , Jul 29, 2017 |  BioCentury  |  Finance

Potentiator potential

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor. On July 24, Effector closed a $19.3 million...
17:52 , Jul 28, 2017 |  BC Week In Review  |  Financial News

Effector raises $38.6M in series C

Cancer company Effector Therapeutics Inc. (San Diego, Calif.) raised $38.6 million in a series C round led by new investor Pfizer Venture Investments on July 24. Also participating were new investor Alexandria Venture Investments and...
14:06 , Jul 24, 2017 |  BC Extra  |  Financial News

Effector raises $38.6M in series C

Cancer company Effector Therapeutics Inc. (San Diego, Calif.) raised $38.6 million in a series C round led by new investor Pfizer Venture Investments. Also participating were new investor Alexandria Venture Investments and existing investors U.S....
18:49 , Jul 21, 2017 |  BC Week In Review  |  Financial News

NeuroVia raises $14M in series A

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million on July 20 in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and...
15:30 , Jul 20, 2017 |  BC Extra  |  Financial News

NeuroVia raises $14M in series A

Rare disease company NeuroVia Inc. (San Francisco, Calif.) raised $14 million in a series A round led by Novartis Venture Fund (NVF) and Sanofi-Genzyme BioVentures (SGBV). Also participating were BioMed Ventures and Enso Ventures. Founder...
01:15 , Feb 20, 2016 |  BC Extra  |  Financial News

Effector expands series B round

Effector Therapeutics Inc. (San Diego, Calif.) raised an additional $16 million in series B funding, bringing the round's total to $56 million. The new funds came from new investor Sectoral Asset Management, as well as...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Effector's expansion

Effector Therapeutics Inc. had planned to complete a Phase I/II trial of eFT508 with existing cash, but preclinical data showing the compound's activity in a wide range of tumor types persuaded investors to back a...